REG - Roquefort Theraptcs. - Transaction Update & Notice of Intention to Delist

Roquefort TherapeuticsAnnouncement

25/02/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nRSY2491Ua&default-theme=true

RNS Number : 2491U  Roquefort Therapeutics PLC  25 February 2026

25 February 2026

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Transaction Update & Intention to delist from the Main Market

 

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company,
is pleased to announce the proposed transaction with Coiled Therapeutics, Inc.
("Coiled USA") and A2A Pharmaceuticals, Inc. ("A2A Pharma"), pursuant to which
the Company will acquire the worldwide exclusive rights to AO-252, a drug
candidate that binds to TACC3 for the treatment of cancers with unmet medical
needs is nearing completion (the "Acquisition") which is conditional on the
admission of the Company's issued and to be issued share capital being
admitted to the AIM market of London Stock Exchange ("AIM Market")
("Admission").

 

The Company and its professional advisers are currently finalising
documentation relating to the equity fundraise which is being undertaken in
conjunction with the Acquisition (the "Fundraise"), along with the Company's
AIM Admission Document and Notice of General Meeting, which is expected to be
published in the coming days (see below) (the, Fundraise, Acquisition and
Admission together referred to as the "Transaction").

 

Intention to delist from the Main Market

In conjunction with the Transaction, the Company announces its intention to
cancel the listing of the Company's ordinary shares on the Equity Shares
(Transition) category of the Official List of the Financial Conduct Authority
("FCA") and to cancel the trading of its ordinary shares on the Main Market of
the London Stock Exchange (the "Delisting").

 

As a company listed on the Equity Shares (Transition) category, the Company is
not required to obtain the approval of its shareholders for the Delisting but
is required under UK Listing Rule 21.2.17 to give at least 20 business days'
notice of the intended cancellation.

 

Accordingly, the Company has requested that: (i) the FCA cancel the listing of
its ordinary shares on the Official List of the FCA; and (ii) the London Stock
Exchange cancels the admission to trading of the ordinary shares on the Main
Market for listed securities of the London Stock Exchange.

 

It is anticipated that the Delisting will become effective in not less than 20
business days. Full details regarding the specific timing of the Delisting,
the Company's proposed readmission to the AIM Market, and the completion of
the Transaction, will be provided shortly when the Company announces the
publication of its AIM Admission Document.

 

Note

Further information regarding the Transaction, AO-252 and the AO-252 Licence
Agreement is set out in the Company's RNS announcements dated 8 September
2025, 16 October 2025, 18 November 2025 and 12 December 2025.

 

Regulatory Information

This Announcement contains inside information for the purposes of the UK
version of the market abuse regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR").

 

ENDS

 

 

Enquiries:
 
 Roquefort Therapeutics plc                                 +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker to the Company)     +44 (0)20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Shard Capital Partners LLP (Broker to the Company)         +44 (0)20 4530 6926

 Damon Heath
 CPS Capital Group (Broker to A2A Pharma & Coiled USA)      +61 (0)8 9223 2222

 Jason Peterson / David Valentino
 Burson Buchanan (Public Relations)                         +44 (0)20 7466 5000

 Henry Harrison Topham / Jamie Hooper / Toto Berger

 

LEI: ‎254900P4SISIWOR9RH34

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

 

About Coiled USA

Coiled USA is a clinical stage oncology company and is a spin-out of A2A
Pharma. Coiled USA holds the exclusive worldwide rights to AO-252, a novel,
brain-penetrant small molecule inhibitor designed to disrupt TACC3
protein-protein interactions.  Coiled USA has advanced the AO-252 program
through pre-clinical development and IND approval and commenced Phase I trials
in the USA (trials ID: NCT06136884).  Coiled USA is actively enrolling
patients to test for safety and efficacy in patients whose cancer has
progressed on other treatments.

 

About A2A Pharma

A2A Pharma is a private, company that uses proprietary computational systems,
including generative AI with its SCULPT™ platform to accelerate the
development of novel drug alternatives for life threatening diseases like
cancer.  This enables a more efficient process than traditional trial and
error approaches to drug discovery.

 

A2A Pharma aims to develop therapies to early clinical stages and then spin
them out into standalone entities to progress them through clinical
development.  In 2018, A2A Pharma spun out its MLL-Menin program to Biomea
Fusion, Inc. ("Biomea Fusion"), a company that completed an IPO on Nasdaq in
2021 raising US$153 million and listing with a market capitalisation of US$464
million.  Post-IPO Biomea Fusion's market capitalisation reached a peak of
over US$1 billion.

 

Further information on A2A Pharma can be found at: https://www.a2apharma.com/
(https://www.a2apharma.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCTIMMTMTMTTJF



            Copyright 2019 Regulatory News Service, all rights reserved